Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16328932 | 0.86 | CA1 (0.56) | CA1CA2ELANEMAPTTDP1 | |
| SCHEMBL15779472 | 0.86 | MAPT (0.50) | PREPELANEMAPTTDP1L3MBTL1 | |
| SCHEMBL8906116 | 0.86 | CA1 (0.56) | PREPCA1CA12CA9CA2 | |
| SCHEMBL11957482 | 0.85 | CA1 (0.38) | CA1CA2ELANEMAPTTDP1 | |
| SCHEMBL2500559 | 0.84 | ELANE (0.52) | PREPCA1CA12CA9ELANE | |
| SCHEMBL7558007 | 0.83 | CA12 (0.39) | PREPCA1CA12CA9MAPT | |
| SCHEMBL6542930 | 0.82 | CA1 (0.52) | PREPCA1CA12CA9CA2 | |
| SCHEMBL936407 | 0.82 | MAPT (0.53) | PREPCA1CA12CA9MAPT | |
| SCHEMBL10126374 | 0.82 | CA12 (0.52) | CA1CA12CA9CA2ELANE | |
| SCHEMBL20100933 | 0.82 | TDP1 (0.52) | MAPTTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180116993-A1 | MODULATORS OF FARNESOID X RECEPTOR AND METHODS FOR THE USE THEREOF | XIAMEN UNIVERSITY (CN) | 2018-05-03 | — | — | US | disclosed |
| US-8242144-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| US-20110082176-A1 | Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases | RESVERLOGIX CORP. | 2011-04-07 | — | — | US | disclosed |
| US-7846915-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2010-12-07 | — | — | US | disclosed |
| US-20060205792-A1 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | disclosed |
| WO-2006045010-A2 | STILBENES AND CHALCONES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205792-A1 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | APOB, APOL1, HDLBP | PREP 3361/4885CA1 4876/4885CA12 4883/4885 |
| US-20180116993-A1 | MODULATORS OF FARNESOID X RECEPTOR AND METHODS FOR THE USE THEREOF | NR1H4, FABP1, NR1H2 | PREP 4194/4885CA1 4479/4885CA12 4484/4885 |
| US-20110082176-A1 | Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases | APOB, APOL1, HDLBP | PREP 3361/4885CA1 4876/4885CA12 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.